Related to Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate

• Pfizer, CytomX in Up To $635M Cancer Collaboration
  
• Lonza to Produce Anti-RhD Antibodies for LFB’s Phase III Trials
  
• Alnara Selects Lonza for Commercial Manufacture of Pancreatic Insufficiency Therapy
  
• Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody
  
• Cellectis to Apply Its Meganuclease Technology to Engineer Lonza Cell Line
  
• Daiichi Sankyo Becomes First Firm to License BioWa and Lonza’s Fucose-Free mAb Cell Line
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• Stason to Use Lonza’s Gene-Expression System with TNT Antibody Platform
  
• Kalobios Chooses BioWa and Lonza’s Potelligent CHOK1SV Cell Line
  
• Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy
  
• Lonza to Provide Cell-Line and Process-Development Services for Athera’s mAb
  
• Genesis Signs On Lonza as Production Partner for Cancer Cell Therapy
  
• Agennix Contracts Lonza for Commercial Manufacturing of Its Oral NSCLC Immunotherapy
  
• Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
  
• FivePrime Licenses BioWa, Lonza’s Cell Line for Anticancer Antibody Pipeline
  
• Lonza to Manufacture OncoMed’s Anticancer Antibody Pipeline
  
• Genmab, ADC Using Warheads to Make New Antibody-Drug Conjugate
  
• Medarex Taps Lonza for Biomanufacturing
  
• Genmab Taps into Seattle's ADC Technology to Develop Anticancer HuMax-TF Conjugate
  
• Seattle and Genmab Sign Antibody-Drug Conjugate Agreement in Cancer